Manufacturing

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University, spoke about trends in continuous manufacturing of OSD drugs.

Johannes Khinast, PhD, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria, spoke about continuous manufacturing of OSD drugs.

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Dave DiProspero, director of Pharmaceutical Process Technology at CRB, spoke about equipment trends in solid-dosage drug manufacturing.

TCR² Therapeutics will add a second clean room to their manufacturing operations.

GenScript’s new gene synthesis center in Piscataway, NJ, is highly automated to accelerate production time and increase supply chain resiliency for biopharma and synthetic biology.

Gentronix has expanded it lab facilities and increased capacity for genetic, ocular, and skin toxicology testing.

Thermo Fisher Scientific showcases its new mass spectrometry and chromatography solutions at the ASMS Conference on Oct. 31–Nov. 4, 2021.

Lonza is expanding its exosomes development and manufacturing capabilities with the acquisition of a service unit from Exosomics and a manufacturing facility from Codiak BioSciences.

The increased flow of data from laboratory studies requires a data management strategy to optimize study success.

The researchers will use 3D printing to design novel flow reactors and static mixers.

Janssen Sciences Ireland was honored for its project execution of a large-scale expansion of biologics drug substance fed-batch capacity.

Advances in simulation and the development of digital twins.

Machine and material innovations yield more efficient, sustainable processes for pharmaceutical packaging, including vaccine vials.

Best practices help mitigate generic drug shortages.

Manufacturing capacity expansion is high on the agenda for many bio/pharma companies and service providers in Europe.

The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.

The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.

Global CDMO, ten23 health, has acquired filling technology and drug product manufacturing expert, swissfillon, enhancing its integrated offering.

The second part of the CPhI Annual Report has predicted an accelerated rate of change in pharma manufacturing and supply over the coming five years.

SGS’s new Antwerp, Belgium, clinical research site will house both clinical trial patients and good manufacturing practice drug manufacturing, and its Glasgow, UK, biosafety testing site now has increased testing capacity.

A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.

EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.

The $19 million contract will expand production capacity of Aptar’s Activ-Film technology, which is used in COVID-19 testing kits.

ANGUS’ planned expansion will double its tromethamine buffer production capacity.

The Pharmaceutical Technology and BioPharm International editors host industry experts in serialization and aseptic processing.

Evonik’s LIPEX Flow extruder is a new version of its high-pressure equipment for manufacturing liposomal drug products.

Knowledge management has gained increasing importance in the pharmaceutical industry over the past 10–15 years

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.